|Articles|May 22, 2018

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

Princeton, NJ – May 22, 2018 – WCG™ (WIRB-Copernicus Group®) Clinical Services Division, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company’s new office in Tokyo, Japan. WCG’s expanded presence in the Asia-Pacific region will strengthen its ability to support increasingly complex, global clinical trials, particularly in the critical areas of drug and diagnostic development for oncology and central nervous system (CNS) diseases.    “WCG’s Tokyo office will be home to our Clinical Services Division in Asia, as well as a center of excellence for our growing Patient Engagement Group,” said Donald A. Deieso, PhD, chairman and CEO of WCG. “By expanding WCG’s footprint abroad, we are helping to ensure that every trial- especially the most complicated and challenging ones-can benefit from our latest advances in trial optimization, signal detection and patient recruitment.”   WCG maintains an active presence in 65 countries around the world, helping research sponsors, contract research organizations (CROs) and investigative sites to work together more effectively to conduct faster, safer, and more predictable clinical trials.    In the past decade, Asia has become an increasingly attractive destination for clinical research, with a clinical trials infrastructure designed to foster speed, cost effectiveness and quality.  With a population of more than four billion people, Asia also provides research sponsors with access to a large number of patients for clinical trial recruitment.     About WCG (WIRB-Copernicus Group)WCG (WIRB-Copernicus Group) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry's first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protections. For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical.


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.